Margriet Kwint1, Barbara Stam1, Cécile Proust-Lima2, Viviane Philipps2, Trynke Hoekstra3, Else Aalbersberg4, Maddalena Rossi1, Jan-Jakob Sonke1, José Belderbos1, Iris Walraven5. 1. Department of Radiation Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 2. INSERM, Bordeaux Population Health Research Center, UMR 1219, Univ. Bordeaux, France. 3. Amsterdam Public Health Research Institute, Department of Health Sciences, VU University Amsterdam, The Netherlands. 4. Department of Nuclear Medicine, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 5. Department of Radiation Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: i.walraven@nki.nl.
Abstract
INTRODUCTION: The aim of this study was to identify subgroups of locally advanced NSCLC patients with a distinct treatment response during concurrent chemoradiotherapy (CCRT). Subsequently, we investigated the association of subgroup membership with treatment outcomes. METHODS: 394 NSCLC-patients treated with CCRT between 2007 and 2013 were included. Gross Tumor Volume (GTV) during treatment was determined and relative GTV-volume change from the planning-CT was subsequently calculated. Latent Class Mixed Modeling (LCMM) was used to identify subgroups with distinct volume changes during CCRT. The association of subgroup membership with overall survival (OS), progression free survival (PFS) and local regional control (LRC) was assessed using cox regression analyses. RESULTS: Three subgroups of GTV-volume change during treatment were identified, with each subsequent subgroup showing a more profound reduction of GTV during treatment. No associations between subgroup membership and OS, PFS nor LRC were observed. Nonetheless, baseline GTV (HR1.42; 95%CI 1.06-1.91) was significantly associated with OS. CONCLUSIONS: Three different subgroups of GTV-volume change during treatment were identified. Surprisingly, these subgroups did not differ in their risk of treatment outcomes. Only patients with a larger GTV at baseline had a significantly worse OS. Therefore, risk stratification at baseline might already be accurate in identifying the best treatment strategy for most patients.
INTRODUCTION: The aim of this study was to identify subgroups of locally advanced NSCLCpatients with a distinct treatment response during concurrent chemoradiotherapy (CCRT). Subsequently, we investigated the association of subgroup membership with treatment outcomes. METHODS: 394 NSCLC-patients treated with CCRT between 2007 and 2013 were included. Gross Tumor Volume (GTV) during treatment was determined and relative GTV-volume change from the planning-CT was subsequently calculated. Latent Class Mixed Modeling (LCMM) was used to identify subgroups with distinct volume changes during CCRT. The association of subgroup membership with overall survival (OS), progression free survival (PFS) and local regional control (LRC) was assessed using cox regression analyses. RESULTS: Three subgroups of GTV-volume change during treatment were identified, with each subsequent subgroup showing a more profound reduction of GTV during treatment. No associations between subgroup membership and OS, PFS nor LRC were observed. Nonetheless, baseline GTV (HR1.42; 95%CI 1.06-1.91) was significantly associated with OS. CONCLUSIONS: Three different subgroups of GTV-volume change during treatment were identified. Surprisingly, these subgroups did not differ in their risk of treatment outcomes. Only patients with a larger GTV at baseline had a significantly worse OS. Therefore, risk stratification at baseline might already be accurate in identifying the best treatment strategy for most patients.
Authors: C Ostheimer; M Mäurer; N Ebert; D Schmitt; D Krug; R Baumann; C Henkenberens; F A Giordano; L Sautter; Guerra López; D F Fleischmann; M Niyazi; L Käsmann; D Kaul; A H Thieme; C Billiet; S Dobiasch; C R Arnold; M Oertel; J Haussmann; T Gauer; Y Goy; C Suess; S Ziegler; C M Panje; C Baues; M Trommer; T Skripcak; D Medenwald Journal: Strahlenther Onkol Date: 2021-01-07 Impact factor: 3.621